Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „moderate“
Suchtreffer
Begriffe & Kennungen
Edurant · 4.8 · All ADRs were mild or moderate. ADRs reported in at least 2 participants, regardless of severity, were: vomiti
Eintrag öffnenEfavirenz Teva · 4.8 · Adverse reactions of moderate or greater severity with at least possible relationship to treatment regimen (ba
Eintrag öffnenEfavirenz Teva · 4.8 · Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first two weeks of init
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.8 · 30 Rash In clinical studies of efavirenz, rashes were usually mild-to-moderate maculopapular skin eruptions th
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Mylan · 4.8 · Rash: In clinical studies of efavirenz, rashes were usually mild-to-moderate maculopapular skin eruptions that
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Mylan · 4.8 · Skin and subcutaneous tissue disorders: Very common rash (moderate-severe, rash 11.6%, all grades, 18%)3 Commo
Eintrag öffnenEklira Genuair · 4.8 · A placebo-controlled trial in 1791 patients with moderate to very severe COPD treated with Eklira Genuair up t
Eintrag öffnenElebrato Ellipta · 4.8 · In a 52-week study, with a total of 10 355 patients with COPD and a history of moderate or severe exacerbation
Eintrag öffnenEmend · 4.5 · Aprepitant (125 mg/80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also a
Eintrag öffnenEmend · 4.5 · Aprepitant (125 mg/80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also a
Eintrag öffnenEmend · 4.5 · Effect aprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition As a moderate inhibitor
Eintrag öffnenEmend · 4.5 · Effect of aprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition As a moderate inhibi
Eintrag öffnenEmend · 4.5 · Immunosuppressants During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in
Eintrag öffnenEmend · 4.5 · Immunosuppressants During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in
Eintrag öffnenEmgality · 4.8 · Injection site pain or reactions The majority of reactions related to the injection site were mild to moderate
Eintrag öffnenEmgality · 4.8 · Injection site pain or reactions The majority of reactions related to the injection site were mild to moderate
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEmselex · 4.5 · When co-administered with moderate CYP3A4 inhibitors such as erythromycin, clarithromycin, telithromycin, fluc
Eintrag öffnenEmselex · 4.5 · When co-administered with moderate CYP3A4 inhibitors such as erythromycin, clarithromycin, telithromycin, fluc
Eintrag öffnen